A New Generation of Drug Therapies Requires New Business Strategies.

The life sciences industry is undergoing a significant shift in drug discovery and development, moving towards advanced therapeutic modalities (ATMs) such as engineered cell therapies, gene therapies, and nucleic acid therapies. This shift is disrupting the industry and necessitates new business strategies, investments, and risk management. ATMs have seen significant growth and investment, with analysts predicting that ATM drug sales may reach a market value of $45 billion to $60 billion by 2027. The unique characteristics of ATMs, such as their design, modularity, and complex manufacturing processes, require stakeholders to focus on manufacturing speed, cost, and consistency. Failure to address manufacturing early on can have costly consequences. Biopharma companies must proactively manage their manufacturing and supply chain strategy, considering factors such as IP control, cost, and strategic value. Contract development and marketing organizations (CDMOs) must invest in enabling tools, technologies, and talent to support complex ATM manufacturing processes. Suppliers of raw materials, tools, and equipment can benefit from the growing demand for GMP-grade materials in ATM production. They should offer innovative solutions to address key bottlenecks in the market and secure ongoing supplier roles. Stakeholders should recognize that ATMs are moving into the mainstream and develop strategies to participate in the next wave of medical biotechnology innovations. [Extracted from the article]